The biopharmaceutical equipment industry is showing a high prosperity and will usher in a new outlet for local substitution

【Pharmaceutical Network Market Analysis】In recent years, the state has successively issued a series of policies
such as the "14th Five-Year Plan for the Development of Biological Industry" and "Made in China 2025".
Affected by favorable policies, the scale of China's biopharmaceutical market is expanding, reaching 464.
4 billion yuan in 2021, and according to this trend, the industry is expected to continue to grow at an average annual compound growth rate of 18% in the next few years, and reach 59 billion yuan
in 2030.
The biopharmaceutical equipment industry may usher in a new outlet for local substitution! It is worth noting that analysts pointed out that in the context of the rapid development of the biopharmaceutical industry, the demand for related pharmaceutical products by biopharmaceutical manufacturers will continue to grow, and it is expected that the industry will have greater growth space
in the future.
It is understood that pharmaceutical equipment runs through the whole chain of biopharmaceuticals, including culture media, fermenters, bioreactors, biological separation and purification and ultrafiltration systems, preparation equipment, lyophilization equipment, etc
.
On the whole, although at present, domestic reagents and consumables have achieved localized substitution, and even broken the monopoly of foreign capital; However, many high-end instruments and equipment that are difficult to research and develop and have high technical barriers are still "stuck in the neck" by foreign-funded enterprises, and the localization rate is relatively low
.
In this regard, the industry believes that China's biopharmaceutical equipment and consumables market, as a rapidly developing and potential market, will have broader prospects in the high-end market in the future
.
In fact, in recent years, as local enterprises continue to increase investment in innovation and R&D, as well as domestic substitution brought about by the epidemic, the entire domestic pharmaceutical equipment industry is accelerating its transformation and upgrading
from low-end to high-end.
At present, local pharmaceutical giants represented by Chutian Technology and Dongfulong have actively developed their layout in this field and have begun to achieve certain results
.
Among them, Dongfulong began to lay out the bioengineering track as early as 2016, and in 2021, the company acquired Qianchun Biotechnology and invested in Saipu, gradually expanding
to the field of downstream consumables/devices.
From 2019, the income of its bioengineering sector began to generate income, and in 2019, the income of bioengineering single machines and systems reached 69.
9451 million yuan, and in the following years it also maintained a high growth trend, increasing by 220% and 305.
15% respectively from 2020 to 2021, and the proportion of revenue reached 8.
27% and 21.
63
% respectively 。 Chutian Technology also pointed out that the bioengineering sector will become an important part of the company's business performance in the future, the company will focus on the development of biomedical equipment, adopt heavy investment and development of biodrug-related products, and plan to increase the annual sales growth rate of biodrug-related process technology and process equipment to exceed other product lines
.
The company will also benchmark Sartorius in the field of biology to complete the relevant product series and industrial chain
.
It is understood that in 2021, Chutian Technology has successively established Chutian Tops and Chutian Microspheres, which are respectively used in the production and sales of related disposable process equipment, consumables and software in the field of biopharmaceuticals, as well as the development and production
of biopharmaceutical process products such as disposable bioreactors, liquid preparation bags, storage bags and their membranes.
In addition, at the end of February this year, Chutian Technology announced the establishment of a holding company, Chutiansi Weikang Gene, which is committed to promoting the layout
in the field of biotechnology.
In addition, Canaan Technology has also said that pharmaceutical dispensing systems, intelligent logistics systems and pharmaceutical R&D services for bioinnovative drugs are the company's key development areas
.
At present, the company has fully laid out the upstream and downstream fields of biopharmaceuticals, and the process has always run through the whole process, providing overall solutions
for process research, core equipment, consumables and system engineering.
Industry analysts believe that in the future, under the background of achieving import substitution of biopharmaceutical equipment and accelerating the development of high-end markets, domestic pharmaceutical machine giants with relatively rich experience, large R&D investment and earlier layout are expected to usher in more benefits
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.